Gri Bio Inc (GRI)

Apr 24, 2025

GRI Bio Inc (GRI) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com

Apr 24, 2025

Apr 17, 2025

FY2025 Earnings Forecast for GRI Bio Issued By HC Wainwright - Defense World

Apr 17, 2025

Apr 16, 2025

GRI Bio appoints Withum as new accounting firm By Investing.com - Investing.com Canada

Apr 16, 2025

Apr 16, 2025

GRI Bio Announces Abstract Selected for Poster Discussion - GlobeNewswire

Apr 16, 2025

Apr 16, 2025

Major Scientific Breakthrough: GRI Bio's Novel Pulmonary Fibrosis Treatment Shows Promise - Stock Titan

Apr 16, 2025

Apr 16, 2025

GRI Bio appoints Withum as new accounting firm - Investing.com Australia

Apr 16, 2025

Apr 15, 2025

GRI Bio (NASDAQ:GRI) Given Buy Rating at HC Wainwright - Defense World

Apr 15, 2025

Apr 15, 2025

H.C. Wainwright maintains Buy on GRI Bio stock, $10 target - Investing.com Australia

Apr 15, 2025

Apr 14, 2025

H.C. Wainwright maintains Buy on GRI Bio stock, $10 target By Investing.com - Investing.com South Africa

Apr 14, 2025

Apr 09, 2025

GRI stock touches 52-week low at $1.2 amid market fluctuations - Investing.com

Apr 09, 2025

Apr 04, 2025

GRI Bio regains compliance with Nasdaq’s minimum bid price rule - MSN

Apr 04, 2025

Apr 03, 2025

GRI Bio Announces Closing of $5.0 Million Public Offering - The Manila Times

Apr 03, 2025

Apr 02, 2025

GRI Stock Down on Public Offering Despite Encouraging IPF Study Data - MSN

Apr 02, 2025

Apr 02, 2025

Gri Bio Announces Closing Of $5.0 Million Public Offering - MarketScreener

Apr 02, 2025

Apr 02, 2025

GRI Bio Raises $5M, Eyes $18.3M Total Potential for Breakthrough Autoimmune Treatment - Stock Titan

Apr 02, 2025

Apr 02, 2025

GRI Stock Down On Public Offering Despite Encouraging IPF Study Data - Barchart.com

Apr 02, 2025

Apr 02, 2025

GRI Bio Shares Rebound In After-Hours Trading - Stocks Telegraph

Apr 02, 2025

Apr 01, 2025

GRI Bio (GRI) Reports Positive Interim Safety Results for IPF Tr - GuruFocus

Apr 01, 2025

Apr 01, 2025

Street can a-GRI on phase IIb safety win in IPF with tazarotene - BioWorld MedTech

Apr 01, 2025

Apr 01, 2025

GRI Bio Announces $5 Million Public Offering Amid Market Decline - Nasdaq

Apr 01, 2025

Apr 01, 2025

GRI Bio Prices up to $13 Million Equity Offering - marketscreener.com

Apr 01, 2025

Apr 01, 2025

GRI Bio announces $5 million public offering - Investing.com

Apr 01, 2025

Apr 01, 2025

GRI Bio announces $5 million public offering By Investing.com - Investing.com India

Apr 01, 2025

Apr 01, 2025

GRI Bio Announces Pricing of $5.0 Million Public Offering - GlobeNewswire

Apr 01, 2025

Apr 01, 2025

GRI Bio Secures $5M Funding Deal: Warrants Could Add $13.3M More - Stock Titan

Apr 01, 2025

Apr 01, 2025

Why Is Nano Cap GRI Bio Stock Skyrocketing On Tuesday?GRI Bio (NASDAQ:GRI) - Benzinga

Apr 01, 2025

Apr 01, 2025

GRI Bio’s IPF drug shows promise in early trial By Investing.com - Investing.com South Africa

Apr 01, 2025

Apr 01, 2025

GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ("IPF - The Manila Times

Apr 01, 2025

Apr 01, 2025

GRI Bio reports interim 2-week safety results from Phase 2a study of GRI-0621 - TipRanks

Apr 01, 2025

Apr 01, 2025

GRI Bio’s IPF drug shows promise in early trial - Investing.com

Apr 01, 2025

Apr 01, 2025

Gri Bio IncIDMC Recommends Continuation Of Study With No Safety Concerns - MarketScreener

Apr 01, 2025

Apr 01, 2025

GRI Bio Reports Encouraging Interim 2-Week Safety Results - GlobeNewswire

Apr 01, 2025

Apr 01, 2025

Clinical Trial Breakthrough: GRI-0621 Clears Key Safety Milestone for IPF Treatment - Stock Titan

Apr 01, 2025

Mar 31, 2025

GRI Bio secures global patents for NKT cell modulators By Investing.com - Investing.com South Africa

Mar 31, 2025

Mar 31, 2025

GRI Bio secures global patents for NKT cell modulators - Investing.com

Mar 31, 2025

Mar 31, 2025

GRI Bio announces the granting of two global patents for Europe, Japan - TipRanks

Mar 31, 2025

Mar 31, 2025

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan - GlobeNewswire

Mar 31, 2025

Mar 31, 2025

Global Patent Victory: GRI Bio's Breakthrough NKT Cell Treatment for Autoimmune Disease Gets Dual Approval - Stock Titan

Mar 31, 2025

Mar 28, 2025

Vallon Pharmaceuticals stock plunges to 52-week low of $4.95 By Investing.com - Investing.com South Africa

Mar 28, 2025

Mar 28, 2025

Vallon Pharmaceuticals stock plunges to 52-week low of $4.95 - Investing.com India

Mar 28, 2025

Mar 20, 2025

GRI Bio (GRI) to Release Quarterly Earnings on Thursday - Defense World

Mar 20, 2025

Mar 18, 2025

GRI Bio Participates in a Virtual Investor CEO Connect Segment - The Manila Times

Mar 18, 2025

Mar 18, 2025

GRI Bio's Breakthrough IPF Drug Shows Promise, Key Data Coming Next Quarter - StockTitan

Mar 18, 2025